June 10, 2020
Oncolys BioPharma said on June 9 that it has agreed to wind up a license agreement with China’s Jiangsu Hengrui Medicine for its oncolytic virus telomelysin (OBP-301) in China, Hong Kong, and Macau. The company will seek a new partner...read more